期刊文献+

2006-2011年无乳链球菌的临床分布及药敏监测 被引量:8

Clinical distribution and drug sensitivities of Streptococcus agalactiae in hospital
原文传递
导出
摘要 目的调查分析无乳链球菌(GBS)的耐药情况及其临床分布,为临床合理用药提供依据。方法对临床各科室送检各类标本进行无乳链球菌的培养,经ATB-Expression细菌分析系统进行鉴定和药敏试验;所有资料采用WHONET 5.6软件进行回顾性分析。结果共分离448株GBS,临床标本分离率最高的是泌尿生殖道分泌物(86.8%),科室检出最多的是妇产科(85.0%);药敏结果显示:耐药率最高的是四环素94.9%,其次是红霉素80.1%和克林霉素62.7%,其他耐药率分别为左旋氧氟沙星36.4%,奎奴普丁/达福普汀20.3%,氯霉素16.3%,头孢噻肟1.1%,青霉素0.2%;呋喃妥因、万古霉素和利奈唑胺耐药率均为0%;克林霉素耐药率表现出下降趋势,左旋氧氟沙星呈现上升趋势。结论加强无乳链球菌的培养检测,关注无乳链球菌的耐药趋势;提高临床重视并指导临床合理用药和治疗。 Objective To investigate the drug susceptibility and distribution of the Streptococcus agalactiaes and provide the evidence for clinical drug usage. Methods Various types of clinical specimens were cultured for Streptococcus agalactiae examination. 448 clinical isolates of Streptococcus agalactiaes (GBS) were identified and their drug sensitivities were determined by ATB-Expression system, and all of the data was analyzed by WHONE TS. 6 Software. Results A total of 448 strains were isolated; the isolation rate of urogenital tract secretion was the highest (86.8%), and most of the strains came from the department of Obstetrics and Gynecology (85.0%). The resistance rates of GBS to tetracycline was the the highest (94.9%), followed by erythromycin (80.1% ) and clindamycin (62.7%). The resistance rates to other antibiotics were as follows: levofloxacin 36.4%, moxifloxacin 20.8%, quinupristin/dalfopristin 20.3%, chloramphenicol 16.3%, cefotaxime 1.1%, peni- cillin 0.2% ; nitrofurantoin, vancomycin and linezolid 0%. The resistance rate to Clindamycin showed a downward trend, while that to levofloxacin showed an upward trend. Conclusion The detection of Streptococcus agalactiae and their resistance trend should be paid close attention for improving and guiding the clinical rational medication and treatment.
机构地区 浙江萧山医院
出处 《中国微生态学杂志》 CAS CSCD 2012年第11期1016-1018,共3页 Chinese Journal of Microecology
关键词 无乳链球菌 感染 药敏结果 Streptococcus agalactiae Infection Drug susceptibility
  • 相关文献

参考文献7

二级参考文献51

共引文献151

同被引文献82

  • 1Tami H, Skoff M, Farley M, et al.Inereasing Burden of Invasive Group B Streptococcal Disease in Nonpregnant Adults, 1990 - 2007[J].Clinical Infectious Diseases,2009,49: 85-92.
  • 2CLSI.Performance standards for antimicrobial susceptibility testing[S]. Twentieth informational supplement.M 100-$21,2011 : 93-95.
  • 3Dany De Mouy, Jean-Didier Cavalln, Roland Leclereq.Antihiotic Susceptibility and Mechanisms of Erythromycin Resistance in Clinical Isolates of Streptococcus agalactiae: French Multicenter Study [J]. Antimicrohial Agents and Chemotherapy, 2001,45: 2400.
  • 4Behrman RE;沈晓明;朱建幸;孙锟.尼尔森儿科学[M]{H}北京:北京大学医学出版社,20071102-1107.
  • 5CLSI. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement.M100-S21[J].Pennsylvania,2011.93-95.
  • 6Schrag S,Gorwitz R,Fultz-Butts K. Prevention of perinatal group B strep to coccal disease.Revised guidelines from CDC[J].{H}Morbidity and Mortality Weekly Report Recommanditions and Reports,2002,(RR-11):1-22.
  • 7Ronald SG, Stephanie S, Anne S. Perinatal infections due to group B streptococei [J]. Obstet Gynecol, 2004, 104 (5) : 1062-1076.
  • 8Curry L, Mahmood TA, Hughes R. The ethics of screen ing for group B streptococcus in pregnancy[J]. Obstet Gynecol,2014,24(2) :62-64.
  • 9Oh W. Early onset neonatal group B streptococcal sepsis [J]. Perinatol, 2013,30(2) : 143-148.
  • 10Verani JL,Schrag SJ. Prevention of peifnatal group B strepto- coccal disease revised guidelines from CDC 2010[J]. MMWR Reeomm Rep, 2010,59 (RR/10) : 1-36.

引证文献8

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部